<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval
Image Overlay - First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval

First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval

December 10, 2020

First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval

The U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) – the first drug for to be used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. Yourway is dedicated to supporting clinical trials for innovative and badly needed drugs like this.

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply New England

April 14-15, 2026
Boston, MA

GCSG 2026 US Conference

April 26-29, 2026
San Diego, CA

Media

Articles

Why Integration Matters in Clinical Supply Chains

Open chat
Come chat with us!
Hello! How can I help you?